ED1 Antimicrobial Resistance in US Hospitals: Burden and VALUE of Investment in Developing New Treatments

This research aims to quantify the burden of antimicrobial resistance (AMR) from the perspective of hospital stakeholders and the value of continued investment in developing new treatments.

Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: W. Iacobucci, C.V. Siego, T. Dall, N. Wallin Bernhardsson, J. Ulrich, J.S. Dougherty Tags: Economic Evaluation Applications: Burden and Value of Therapies Source Type: research